Company Encyclopedia
View More
name
Impact BioMedical
IBO.US
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances.
4.609 T
IBO.USMarket value -Rank by Market Cap -/-

Financial Score

19/12/2025 Update
E
PharmaceuticalsIndustry
Industry Ranking180/183
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-455.13%E
    • Profit Margin-176764.00%E
    • Gross Margin94.44%A
  • Growth ScoreD
    • Revenue YoY0.00%C
    • Net Profit YoY-3893.22%E
    • Total Assets YoY-61.01%E
    • Net Assets YoY-125.77%E
  • Cash ScoreC
    • Cash Flow Margin-0.06%D
    • OCF YoY0.00%C
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreE
    • Gearing Ratio148.62%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Impact Biomedical Inc. Files Preliminary Information Statement Outlining Authorized Corporate Actions

    Impact BioMedical Inc. shareholders have approved key corporate actions, including a Reverse Stock Split and changes to Authorized Shares, on March 28, 2025. The full filing is available via EDGAR (Ref. ID: 0001493152-25-027284).

    Reuters·
    US
    IBO
    +46.26%
    Reuters·
    US
    IBO
    +46.26%

    Impact BioMedical | 10-Q: FY2025 Q3 Revenue: USD 18 K

    LB filings·
    US
    IBO
    +46.26%
    LB filings·
    US
    IBO
    +46.26%

    Impact Biomedical Inc. held annual shareholder meeting

    Impact Biomedical Inc. held its annual shareholder meeting on November 5, 2025, where stockholders elected eight members to the board of directors, including Frank D. Heuszel and Elise Brownell. Additionally, the appointment of Grassi & Co. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.

    Reuters·
    US
    IBO
    +46.26%
    Reuters·
    US
    IBO
    +46.26%

    Impact BioMedical Inc. Approves Issuance of 31.9 Million Shares to DSS, Inc

    Impact BioMedical Inc. has approved the issuance of 31.9 million shares to DSS, Inc. This decision was made by the Board of Directors and majority stockholders on July 14, 2025, and will be implemented after a designated period. The company, based in Houston, Texas, aims to advance its strategic objectives in the biomedical sector.

    Reuters·
    US
    IBO
    +46.26%
    Reuters·
    US
    IBO
    +46.26%

    Impact BioMedical | 10-Q: FY2025 Q2 Revenue: USD 7 K

    LB filings·
    US
    IBO
    +46.26%
    LB filings·
    US
    IBO
    +46.26%
    © 2025 Longbridge｜Disclaimer